Crimson Publishers Publish With Us Reprints e-Books Video articles

Abstract

Novel Research in Sciences

Selective Estrogen Receptor Degraders in the Arsenal against Estrogen Receptor Positive Breast Cancer

  • Open or CloseMatthew Ramjiawan1, Paramjit S Tappia1* and Bram Ramjiawan2

    1Asper Clinical Research Institute & Office of Clinical Research, St. Boniface Hospital, Canada

    2Department of Pharmacology & Therapeutics, Rady Faculty of Health Sciences, University of Manitoba, Canada

    *Corresponding author:Paramjit S Tappia, Asper Clinical Research Institute & Office of Clinical Research, St. Boniface Hospital, Winnipeg, MB, R2H 2A6, Canada

Submission: June 20, 2020;Published: June 26, 2020

Abstract

In 2018, there were an estimated 18.1 million new cancer cases (17.0 million excluding non-melanoma skin cancer) and 9.6 million cancer deaths (9.5 million excluding nonmelanoma skin cancer) [1]. In women, breast cancer is the most commonly diagnosed cancer as well as the leading cause of cancer death, estimated to be 11.6% [1,2]. Although more than 70% of breast cancer patients in most high-income countries are diagnosed in stages I and II, only 20%-50% of patients in the majority of low- and middle-income countries are diagnosed in these stages [3].

Get access to the full text of this article